Ibrutinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ibrutinib and local guidelines before prescribing.
BTK inhibitor
Mechanism
Bruton tyrosine kinase inhibitor.
Uses
CLL, mantle cell lymphoma, Waldenstrom macroglobulinaemia.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Bleeding, AF, hypertension, diarrhoea, infections.
Interactions
CYP3A4 inhibitors raise levels; anticoagulants increase bleeding.
Contraindications and cautions
Active bleeding, AF caution
Monitoring
FBC, ECG, BP
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Avoid in severe liver impairment
Overdose and reversal
Supportive
Special advice
Hold before and after surgery; ECG and BP monitoring.
More from the textbook: uses, cautions and other points
- Ibrutinib , acalabrutinib, zanubrutinib (BTK) | CLL, mantle cell lymphoma, Waldenström's | Atrial fibrillation , bleeding (care with anticoagulants), hypertension, infections; CYP3A4 interactions
Haematology: Anatomy Physiology and Pharmacology - BTK inhibitors - ibrutinib, acalabrutinib , zanubrutinib - continuous tablets. Side effects: AF , bleeding (caution with anticoagulants), hypertension, infections.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Treat only when symptomatic: BTK inhibitors (zanubrutinib, ibrutinib) or bendamustine-rituximab; plasmapheresis for hyperviscosity. Rituximab can cause an IgM "flare", so use with caution when IgM is very high.
Haematology: Myeloma and Lymphoma - Bleeding | Anticoagulants, antiplatelets, NSAIDs , SSRIs and SNRIs (especially with NSAIDs or anticoagulants), steroids (GI), ibrutinib, herbal products (ginkgo, fish oil - minor)
Haematology: Anatomy Physiology and Pharmacology - Ibrutinib | BTK; AF and bleeding.
Haematology: Anatomy Physiology and Pharmacology - Pulse - tachycardia (anaemia, bleeding, sepsis); bounding (severe anaemia - high output); irregular (AF on anticoagulants; ibrutinib).
Haematology: History and Examination - Venetoclax with ibrutinib (fixed duration).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Ibrutinib / acalabrutinib / zanubrutinib | BTK inhibitors for CLL; AF, bleeding, hypertension, infections.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia
Where it is discussed in the book
- Haematology: Anatomy Physiology and Pharmacology (3 mentions)
- Haematology: History and Examination (1 mention)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (3 mentions)
- Haematology: Myeloma and Lymphoma (3 mentions)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (2 mentions)